Dust Mite Pillow Covers: Do They Help Allergies?
Dust mite pillow covers lower your exposure to mite allergen — but in the landmark Dutch trial of 279 people, they did not significantly improve rhinitis symptoms. Buy them as part of a bedroom routine, not as a cure. The label promise outruns the evidence, and this page shows exactly where the boundary sits.
Applies to: anyone whose pillow or bedding label promises allergy relief — and anyone wondering whether the covers are worth buying.
In a Dutch trial of 279 people with dust-mite allergy, impermeable pillow and mattress covers cut allergen exposure but did not significantly improve symptoms. Here is how to read that, and what else matters — the dust mite pillow covers evidence, held to the same standard as the marketing.
The contradiction is the whole story: the covers do what they physically promise — block allergen — yet the symptoms didn't move. Understanding why that can be true is more useful than any buying guide's verdict, because it tells you what dust mite pillow covers can and cannot do for you. The short version is that exposure and symptoms are not the same thing: you can cut one substantially without moving the other, because symptoms have more than one driver, because the bedroom is not the only exposure, and because a single intervention, however well executed, is a small lever on a large problem. The trials below show that pattern twice — once for rhinitis, once for asthma — and the systematic reviews confirm it.
If a label promises allergy relief, read this page before you buy — that's the reader this was written for. The bedding aisle runs on hope, and hope is a fine thing to sell alongside an honest product. What's not fine is the gap between "reduces exposure" (proven) and "relieves symptoms" (not demonstrated): that gap is where money gets spent without benefit. The dust mite pillow covers market lives in that gap, and this page is the bridge across it — in both directions, because the covers are worth buying for the right reason.
So, do dust mite pillow covers help? They help with exposure, not with symptoms — that is the trial verdict, stated plainly. In the Terreehorst trial, 279 people with allergic rhinitis used impermeable covers on mattress, pillow and duvet for a year; mite allergen in the mattresses fell significantly, but there was no significant effect on any clinical outcome (Terreehorst et al., 2003). A Cochrane review of nine trials reached the same conclusion in different words: impermeable bedding as an isolated intervention is unlikely to offer clinical benefit (Sheikh et al., 2010). Buy the cover to reduce what you breathe in at night, inside a full bedroom routine — not as a treatment.
The zipper is the technology: a pore size too small for mites or their droppings is what separates an encasement from a pretty pillowcase.
What the trials tested
One landmark randomised trial — 279 people with dust-mite allergy, three Dutch university centres, one year — compared impermeable covers for mattress, pillow, and duvet against ordinary covers. Everyone in the trial also received information on general allergen-avoidance measures, so the covers were tested as an addition to a routine, not instead of one. The researchers measured rhinitis severity on a rhinitis-specific visual-analogue scale, a daily symptom score, and nasal allergen provocation testing, and they measured the concentrations of the two main mite allergens, Der p 1 and Der f 1, in dust from mattresses, bedroom floors and living-room floors at the start and after twelve months (Terreehorst et al., 2003).
Two details matter for reading the result. First, the trial encased the full set — mattress, pillow and duvet — so a pillow-only cover was never tested alone, and this page cannot tell you what a pillow cover does by itself. Second, 232 of the 279 people completed the study, which is a solid completion rate for a year-long trial, and the subgroup analyses — by age, exposure level, type and severity of sensitisation, and home characteristics — gave similar results, so the null finding is not hiding in a subgroup (Terreehorst et al., 2003).
The trial is now more than twenty years old, which is a fair criticism — and it is the reason this page also leans on the systematic reviews below, which pool everything published since. The reviews agree with the trial rather than overturning it. That is worth saying plainly: when a 2003 trial and a 2010 Cochrane review and a 55-trial asthma review all point the same way, the age of the trial stops being the story.
What changed and what did not
What changed: the allergen. There was a significant reduction in Der p 1 and Der f 1 concentrations in the mattresses of the impermeable-cover group, with no significant reduction in the control group (Terreehorst et al., 2003). The covers did exactly what their physics promises: they sealed the reservoir shut, and the measurable allergen in the mattress dust fell.
What did not change: the symptoms. There was no significant effect on the clinical outcome measures — not on the rhinitis severity scale, not on the daily symptom score, and not on nasal provocation testing (Terreehorst et al., 2003). The authors' conclusion is worth quoting because it is careful: "Mite-proof bedding covers, as part of a structured allergy-control program, reduced the level of exposure to mite allergens. Despite the success of the intervention, this single avoidance measure did not lead to a significant improvement of clinical symptoms in patients with allergic rhinitis."
Why would exposure fall and symptoms stay put? The trial itself does not answer that, and this page will not invent an answer. The honest candidates are the ones the field discusses: symptoms are driven by total exposure across the whole day, not just the eight hours in bed; by other allergens alongside mites; and by airway hyperreactivity that does not switch off when one trigger falls. A cover changes one input to a system with many inputs. That is not a reason to dismiss the cover — it is a reason to stop expecting it to do the work of a treatment.
The asthma evidence: a second, larger verdict
The rhinitis trial has a companion. In the same issue of the same journal, Woodcock and colleagues ran a double-blind randomised trial of impermeable bed covers in 1,122 adults with asthma, recruited from 154 English general practices (Woodcock et al., 2003). It is four times the size of the rhinitis trial, and it tells the same story with more precision.
The exposure result repeated: Der p 1 in mattress dust was significantly lower in the impermeable-cover group at six months — a geometric mean of 0.58 micrograms per gram against 1.71 in the control group, P=0.01 — but the difference had faded by twelve months (1.05 against 1.64, P=0.74) (Woodcock et al., 2003). The clinical results did not move at all: there was no significant difference between the groups in morning peak expiratory flow at six months — a difference in means of −1.6 litres per minute, with a 95% confidence interval from −5.9 to 2.7, P=0.46 — nor in the proportion who managed to stop inhaled corticosteroids entirely (17.4% in the cover group against 17.1% in the control group), nor in the mean reduction in steroid dose (Woodcock et al., 2003). The authors' conclusion: impermeable covers, as a single intervention, "seem clinically ineffective in adults with asthma."
The systematic reviews then pool all of it. A Cochrane review of house dust mite avoidance for perennial allergic rhinitis included nine trials with 501 participants; only two of the bedding-cover trials were good quality, seven of the nine trials reported significant reductions in mite load, and the authors concluded that impermeable bedding as an isolated intervention is unlikely to offer clinical benefit — while noting that acaricides looked the most promising of the interventions studied, with the caution that those findings need careful interpretation (Sheikh et al., 2010). A separate Cochrane review of mite control measures for asthma pooled 55 trials with 3,121 patients; for morning peak flow, the most frequently reported outcome, the standardised mean difference was 0.01, with a 95% confidence interval from −0.08 to 0.11 — effectively zero — and there were no significant differences in symptom scores or medication use (Gøtzsche & Johansen, Cochrane, CD001187). Three levels of evidence — one trial, a second larger trial, and two pooled reviews — all agree. That is as settled as this question gets.
One counterpoint, stated with its limits. A small Japanese study of 25 adult atopic asthmatics combined microfine-fibre encasings with one-to-one allergen-avoidance counselling and bedroom cleaning; Der 1 levels fell, asthma symptom scores decreased significantly, and minimum peak expiratory flow increased significantly (Tsurikisawa et al., 2013). It is a combined programme, not a cover alone, with 25 people and no blinding — so it does not overturn the reviews. What it suggests, honestly, is that covers inside a full programme may help where covers alone do not. That is the same conclusion the routine section below reaches by a different route.
When covers can still make sense
A negative trial verdict is not a verdict against buying. It is a verdict against buying for the wrong reason. Covers make sense when the goal is exposure reduction rather than symptom relief: you are allergic, you spend a third of your life with your face on a pillow, and you want less of the allergen in your breathing zone at night. That is a legitimate goal, and the covers achieve it — the trials prove the exposure part.
They make the most sense inside a routine, not instead of one. The trial that showed any hint of benefit combined encasings with counselling and cleaning (Tsurikisawa et al., 2013), and the Terreehorst trial itself gave every participant general avoidance advice alongside the covers (Terreehorst et al., 2003). A cover on a pillow you never wash, in a bedroom you never vacuum, is a sealed box around a dirty object. A cover on a washed pillow, in a room you keep dry and clean, is one layer of a system that actually reduces what you breathe.
They make the least sense as a first purchase for someone with no diagnosis. If you have not been tested for dust-mite allergy, a cover is a guess at a cause. Get the test first — skin prick or blood test, through a clinician — and then decide. And if your rhinitis or asthma persists despite a full routine, the next step is a clinician, not a more expensive cover.
The "hypoallergenic" label problem
"Hypoallergenic" on a pillow label is marketing, not a tested claim. No standard stands behind the word, no test certifies it, and no regulator checks it. A pillow can be labelled hypoallergenic because its fill is synthetic, because its cover is tightly woven, or because the manufacturer felt like it — and you cannot tell which from the label.
What matters is the encasement and the wash routine, not the label. A pillow in a sealed encasement with pores below 10 microns, washed regularly, is doing the job regardless of what the label says. A pillow labelled hypoallergenic with no encasement and no wash routine is doing nothing the label promises. Judge construction, not adjectives: ask for the pore size, check the zip seals fully, and wash the thing.
Pore size: the number that actually matters
If there is one number worth knowing on this page, it is 10 microns. In a 1999 laboratory study, researchers pulled dust containing known quantities of mite allergen (Der f 1 and Der p 1) and cat allergen (Fel d 1) across a variety of encasement fabrics. Dust mite allergens were blocked below detectable limits by fabrics with pores of less than 10 microns; fabrics with an average pore size of 6 microns or less blocked cat allergen too (Vaughn et al., 1999). Mite faecal particles — the droppings that carry the allergen — are 10 to 40 microns across, which is why a sub-10-micron pore works: the particle carrying the allergen is bigger than the hole.
That gives you a buying rule that needs no trust in any brand: a cover that states its pore size, below 10 microns, has proved something; a cover that does not state its pore size has proved nothing. Woven microfibre and nonwoven synthetics can both hit the target while still allowing airflow — the study found tightly woven and nonwoven fabrics could block common indoor allergens and still breathe (Vaughn et al., 1999). Plastic, which has no pores at all, blocks everything and breathes nothing; it is the best barrier and the least comfortable, and it tends to trap moisture.
Check the zip as carefully as the fabric. An encasement with a 6-micron pore size and a zip that gapes at the end is not an encasement — it is a bag with a hole in it. The zip should close flush, with no gap, and the cover should fully enclose the pillow, not drape over it.
A bedding routine that moves the needle
No single step in this routine is proven to relieve symptoms on its own. The routine is worth doing because each step reduces exposure, and exposure is the thing the covers are proven to cut. The steps below are allergy guidance and laboratory findings, not trial results, and they are labelled as such.
The weekly routine
- Wash sheets and pillowcases weekly in water hotter than 60°C where the fabric allows it — allergy guidance from ASCIA (ASCIA, 2024). Heat is what kills mites: water at 55°C or above killed all mites in laboratory tests (McDonald & Tovey, 1992).
- Wash the encasement regularly in hot water where the label allows it. A cover that is never washed becomes a reservoir of the allergen it was bought to block.
- Hot tumble dry for at least ten minutes after drying where hot washing is not possible (ASCIA, 2024).
- Encase the full set — mattress, pillows, duvet — because that is what the trials tested. A pillow-only cover was never tested alone (Terreehorst et al., 2003).
- Vacuum the mattress and the bedroom regularly, and keep humidity down: mites need moisture, and a dry bedroom is a less hospitable one. Air the bedding on dry days.
- Keep the bedroom simple. Fewer soft furnishings means fewer mite reservoirs. This is guidance, not a trial result — but it follows directly from where mites live.
Note what is not on the list: dry cleaning. Dry cleaning killed most mites in the laboratory tests but did not reduce the allergen concentration (McDonald & Tovey, 1992), and allergy guidance says so explicitly (ASCIA, 2024). For allergy purposes it is the worst of both worlds.
For the washing itself — temperatures, drying, and what to do with foam and latex — see our guide to how to clean a pillow.
Common mistakes to avoid
Buying the cover and stopping there. The trials show a cover alone does not move symptoms. A cover is one layer of a routine; on its own it is an expensive pillowcase.
Encasing a dirty pillow. Sealing a pillow that has never been washed traps the existing allergen load inside with you. Wash the pillow first, dry it fully, then encase it.
Trusting the label instead of the pore size. "Hypoallergenic" and "allergy-proof" are unregulated words. The number that matters is the pore size, below 10 microns (Vaughn et al., 1999). If the cover does not state it, it has not proved anything.
Ignoring the zip. A cover that gapes at the zip is not sealed. Check that it closes flush before you rely on it every night.
Expecting a cure. The strongest evidence on this page is a negative: covers cut exposure and do not reliably relieve symptoms. Buying one while expecting your rhinitis to vanish is how disappointment gets manufactured.
Skipping the diagnosis. If you have not been tested for dust-mite allergy, a cover is a guess at a cause. Get tested first.
Should you try a cover?
Four questions, adapted from the trials' own logic. Answer them honestly — the result runs entirely in your browser and nothing is sent anywhere.
1. Do you have a diagnosed dust-mite allergy (not just a suspicion)?
2. Are your symptoms clearly worse in the bedroom or on waking?
3. Are you already washing bedding hot weekly and controlling humidity?
4. Would you encase the full set — mattress, pillows, and duvet?
Findings and recommendation
Verdict: buy dust mite pillow covers for exposure reduction as part of a full bedroom routine, not as a symptom cure. The evidence for that sentence is unusually complete: a 279-person randomised trial found no significant symptom improvement despite a significant fall in allergen (Terreehorst et al., 2003); a 1,122-person asthma trial found the same pattern, with the allergen advantage fading by twelve months (Woodcock et al., 2003); a Cochrane review of nine rhinitis trials concluded isolated impermeable bedding is unlikely to offer clinical benefit (Sheikh et al., 2010); and a Cochrane review of 55 asthma trials found a morning peak-flow effect of effectively zero (Gøtzsche & Johansen, Cochrane, CD001187).
What to buy, if you buy: a cover that states a pore size below 10 microns (Vaughn et al., 1999), with a zip that seals fully, for the full set — mattress, pillows and duvet — washed regularly in hot water. What to do alongside it: weekly hot washing, humidity control, and a clinician for the symptoms themselves. And what not to do: do not buy a cover expecting your rhinitis or asthma to improve, because the best evidence we have says it probably will not — and a purchase made on a promise the evidence does not support is the one purchase this site exists to prevent.
What the evidence cannot tell you
The trials are old — 2003 for both landmark trials — and no large trial has repeated them since. The Cochrane reviews pool small, often poor-quality studies, and the rhinitis review explicitly says the trials to date have been small and of poor methodological quality, making definitive recommendations difficult (Sheikh et al., 2010). The asthma review carries a Cochrane editorial note that it predates current reporting standards and should not be used for clinical decision-making (Gøtzsche & Johansen, Cochrane, CD001187). No trial has tested a pillow-only cover. No trial has tested modern microfibre covers against the older vinyl and woven covers the trials used. And no trial has measured what matters most to a buyer — whether people who buy covers feel better — because the trials measured symptom scores, not satisfaction.
What the evidence can tell you is narrower and firmer: covers cut exposure, and cutting exposure alone does not reliably cut symptoms. That is enough to buy wisely. It is not enough to promise relief, and this page does not.
Key takeaways
- A Dutch RCT (n=279, 1 year): impermeable covers cut mite allergen exposure but did NOT significantly improve rhinitis symptoms (Terreehorst et al., 2003).
- A UK asthma trial (n=1,122) found the same pattern: allergen lower at 6 months, no difference in peak flow or steroid use (Woodcock et al., 2003).
- Cochrane reviews agree: 9 rhinitis trials (501 participants) and 55 asthma trials (3,121 patients) found isolated impermeable bedding unlikely to help symptoms.
- The trial encased mattress + pillow + duvet — pillow-only covers were never tested alone.
- Pore size below 10 microns blocks mite allergen below detectable limits (Vaughn et al., 1999); "hypoallergenic" is unregulated marketing.
- Covers make sense as exposure reduction inside a full routine — not as a symptom cure.
- Persistent rhinitis despite the routine deserves a clinician, not a more expensive cover.
Hot washing is the routine's workhorse: heat kills mites, and clean bedding lowers the load the covers then seal in.
Questions people actually ask
Do dust mite pillow covers work?
What pore size blocks dust mites?
How often should you wash dust mite covers?
Do hypoallergenic pillows work?
What water temperature kills dust mites in bedding?
Which pillow materials are worst for dust mites?
Should I wash a dust mite cover before first use?
References
- Terreehorst, I., et al. (2003). Evaluation of impermeable covers for bedding in patients with allergic rhinitis. New England Journal of Medicine, 349(3), 237–246. PubMed: 12867607 / DOI: 10.1056/NEJMoa023171
- Woodcock, A., et al. (2003). Control of exposure to mite allergen and allergen-impermeable bed covers for adults with asthma. New England Journal of Medicine, 349(3), 225–236. PubMed: 12867606 / DOI: 10.1056/NEJMoa023175
- Sheikh, A., Hurwitz, B., Nurmatov, U., & van Schayck, C. P. (2010). House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database of Systematic Reviews, CD001563. PubMed: 20614426 / PMC7061254
- Gøtzsche, P. C., & Johansen, H. K. (2008, updated 2011). House dust mite control measures for asthma. Cochrane Database of Systematic Reviews, CD001187. PubMed: 18425868 / PMC8786269
- Vaughn, J. W., McLaughlin, T. E., Perzanowski, M. S., & Platts-Mills, T. A. E. (1999). Evaluation of materials used for bedding encasement: effect of pore size in blocking cat and dust mite allergen. Journal of Allergy and Clinical Immunology, 103(2), 227–231. PubMed: 9949312 / DOI: 10.1016/S0091-6749(99)70495-1
- McDonald, L. G., & Tovey, E. (1992). The role of water temperature and laundry procedures in reducing house dust mite populations and allergen content of bedding. Journal of Allergy and Clinical Immunology, 90(4), 599–608. DOI: 10.1016/0091-6749(92)90132-L
- Tsurikisawa, N., et al. (2013). Encasing bedding in covers made of microfine fibers reduces exposure to house mite allergens and improves disease management in adult atopic asthmatics. Allergy, Asthma & Clinical Immunology, 9, 44. PubMed: 24499343 / PMC3829998
- Australasian Society of Clinical Immunology and Allergy (ASCIA). (2024). Allergen minimisation. allergy.org.au
Last updated: 2026-11-21 by Adeel Farooq
Updated 21 November 2026 — full rewrite: Terreehorst linked to the correct PubMed record (12867607, not 12867610); Cochrane rhinitis review (Sheikh et al., 2010) and asthma review (Gøtzsche & Johansen) added; Woodcock 2003 asthma trial added; live process notes removed.
How we researched this page
We mapped the reader questions assigned to this guide, then traced every number to its primary source, read first-hand on PubMed or PubMed Central: the Terreehorst 2003 trial (PMID 12867607), the Woodcock 2003 trial (PMID 12867606), the Sheikh 2010 Cochrane review (PMID 20614426), the Gøtzsche & Johansen Cochrane review (PMID 18425868), the Vaughn 1999 pore-size study (PMID 9949312), the McDonald & Tovey 1992 wash-temperature study, and the Tsurikisawa 2013 combined-intervention study (PMID 24499343). The systematic-review check the previous version flagged as outstanding is now done and is reflected in the evidence above. No manufacturer claims were used as evidence. Full method: how we research.